Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEVI-007 (Camoteskimab) in Relapsed or Refractory Multiple Myeloma
NCT04671251Phase 1Completed
- Sponsor
- Avalo Therapeutics
- Start
- Dec 2020
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of camoteskimab in multiple myeloma (MM), sponsored by Avalo Therapeutics. Primary endpoint: Recommended Phase 2 Dose. Started Dec 2020; status: completed.
02
Drugs
camoteskimab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04671251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04671251.